gimli

RUBICON stock AI analysis

RUBICON Stock AI Analysis: Price, PE, 50DMA, Shareholding and Peers

RUBICON RESEARCH LIMITED is a small-cap stock in Healthcare. This Gimli page shows the latest available RUBICON price, returns, 50DMA/200DMA trend, PE, ROE, ROCE, financials, shareholding pattern, and industry peers for Indian stock screening research.

Analyze with AI Open interactive RUBICON stock page

Price

₹1,511.80

1W return

+5.12%

1M return

+11.01%

3M return

+62.99%

6M return

+127.73%

1Y return

n/a

Market cap

₹24,906.95 cr

100.95

19.33

ROE

+19.14%

ROCE

+13.09%

RSI

67.59

Turnover

₹53.01 cr

Why it can matter in screens

Momentum: RUBICON is above 50DMA, below 200DMA; RSI is 67.59.
Returns: 1D +5.02%, 1W +5.12%, 1M +11.01%, 3M +62.99%, 1Y n/a.
Trend levels: 52W high ₹1,511.80, 52W low ₹577.25, off high +0.00%.
Liquidity: latest turnover is ₹53.01 cr; volume vs 20D is +1.20%.
Valuation/profitability: PE 100.95, PB 19.33, ROE +19.14%, ROCE +13.09%.
Growth: 3Y sales CAGR +61.15%, 3Y profit CAGR n/a.

Quick Answers

What is the latest RUBICON stock price?

The latest stored price for RUBICON is Rs 1,511.80 as of 2026-07-20.

Is RUBICON above its 50DMA and 200DMA?

RUBICON is above 50DMA, below 200DMA. The latest 50DMA is 1,234.94 and the latest 200DMA is n/a.

What are RUBICON PE, ROE and ROCE?

RUBICON has PE 100.95, ROE +19.14%, and ROCE +13.09% in Gimli's latest available snapshot.

How has RUBICON performed recently?

RUBICON has returned +11.01% over 1 month, +62.99% over 3 months, and n/a over 12 months in the latest stored data.

Is this stock page investment advice?

No. This page is a data snapshot for screening and research. It is not buy, sell, legal, tax, or investment advice.

Financials and Ownership

Quarterly income statement

Period	Revenue	EBITDA	PAT	EPS
2026-03-31	513.91 cr	121.31 cr	76.78 cr	4.66
2025-12-31	475.53 cr	111.91 cr	72.80 cr	4.46
2025-09-30	412.72 cr	94.99 cr	53.85 cr	3.47
2025-06-30	353.12 cr	79.74 cr	43.30 cr	2.79
2025-03-31	358.15 cr	72.57 cr	36.24 cr	2.20
2024-12-31	313.40 cr	70.39 cr	38.07 cr	2.31

Annual income statement

Year	Revenue	EBITDA	PAT	EPS
2026-03-31	1,753.96 cr	407.96 cr	246.74 cr	15.52
2025-03-31	1,284.27 cr	267.89 cr	167.54 cr	10.82
2024-03-31	656.94 cr	99.55 cr	24.35 cr	1.58
2023-03-31	419.00 cr	43.97 cr	-16.89 cr	-1.11
2022-03-31	417.41 cr	57.45 cr	16.68 cr	32.91

Balance sheet

Period	Assets	Cash	Debt	Equity
2026-03-31	2,326.71 cr	185.65 cr	311.01 cr	1,288.82 cr

Cash flow

Period	OCF	FCF	Cash change
2026-03-31	205.05 cr	-24.12 cr	n/a
2025-03-31	n/a	n/a	n/a

Shareholding Trend

Period	Promoter	FII/FPI	DII	MF	Retail	Pledge
2026-03-31	+59.86%	+7.54%	+10.02%	+7.14%	+22.58%	+0.00%
2025-12-31	+59.99%	+7.99%	+9.45%	+6.61%	+22.57%	+0.00%
2025-10-15	+59.99%	+9.37%	+10.54%	+5.63%	+20.10%	+0.00%

Industry Peers

Symbol	Name	Mcap	PE	ROE	1Y
SUNPHARMA	SUN PHARMACEUTICAL IND L	469,405.90 cr	40.823336	+14.71%	+15.52%
DIVISLAB	DIVI S LABORATORIES LTD	194,269.92 cr	75.650281	+16.19%	+8.71%
TORNTPHARM	TORRENT PHARMACEUTICALS L	169,405.46 cr	78.319677	+17.18%	+42.14%
APOLLOHOSP	APOLLO HOSPITALS ENTER. L	128,040.28 cr	65.380043	+21.03%	+21.93%
CIPLA	CIPLA LTD	116,452.52 cr	30.005339	+11.79%	-2.75%
ZYDUSLIFE	ZYDUS LIFESCIENCES LTD	115,616.29 cr	23.056854	+17.93%	+17.85%
LUPIN	LUPIN LIMITED	113,320.96 cr	21.221472	+26.83%	+28.27%
MAXHEALTH	MAX HEALTHCARE INS LTD	107,290.40 cr	74.382732	+14.33%	-9.32%

Try these prompts

Analyze RUBICON RESEARCH with valuation, momentum and industry peers
Compare RUBICON with other Healthcare stocks
Show small-cap stocks in Healthcare above 50DMA with positive 1M return
Find Healthcare stocks with improving momentum and reasonable valuation

Related screen ideas

Data snapshot: 2026-07-20. Not investment advice.